CAMBRIDGE, MA APR 28TH, 2017 Apr 28th, 2017
Fertility SOURCE clients may now select the GenePeeks test to assess a future child’s risk of disease inheritance, a service that includes consultation with a certified genetic counselor. Donor SOURCE™ donors now have the option to complete pre-test protocols and be identified as “GenePeeks Ready,” which may save prospective parents significant time in their fertility journey.
CAMBRIDGE, MA FEB 28TH, 2017 Feb 28th, 2017
GenePeeks today announced partnerships with two leading fertility organizations: The Donor Solution, an independent egg donation agency, and 3 Sisters Surrogacy, a gestational carrier service. Through these partnerships, more prospective parents will have access to GenePeeks' proprietary preconception genetic screening test.
CAMBRIDGE, MA FEB 1ST, 2017 Feb 1st, 2017
Matt Posard joins the GenePeeks team with more than 25 years of experience successfully commercializing innovative technologies in the life science and molecular diagnostics fields. Over the course of his career, Posard has held influential leadership roles at a number of market leading companies including Illumina, Trovagene and Alere.
CAMBRIDGE, MA JAN 24TH, 2017 Jan 24th, 2017
GenePeeks today announced the launch of its proprietary next-generation screening platform. Powered by Virtual Progeny Analytics (VPA), the patented technology enables high-resolution visibility into the risk of conceiving a child with one or more of 1,000+ heritable diseases.
NEW YORK, NY MAY 1ST, 2016 May 1st, 2016
The study spotlights the need to overhaul screening protocols to take advantage of the tremendous advances in human genomics that have occurred over the past decade.
NEW YORK, NY MARCH 1ST, 2016 Mar 1st, 2016
GenePeeks and Reproductive Medicine Associates of New York (RMA of New York) announce their collaboration and the start of patient recruitment for a study evaluating the clinical performance of GenePeeks’ pre-conception risk prediction technology in comparison to expanded carrier screening.
NEW YORK, NY OCTOBER 29, 2015 Oct 29th, 2015
In this letter to the editor, we highlight an inherent limitation in the carrier screening framework for cystic fibrosis. We argue that computational tools are highly relevant to the development of a more effective response to disease risk identification and management.
NEW YORK, NY JULY 13, 2015 Jul 13th, 2015
It’s wonderful to have an ongoing conversation around genetics and health. We are not in pursuit of the "perfect baby," however that would ever be defined. We want what all parents want — a world where every child has the chance at a healthy future.
SEATTLE, WA (PR WEB) JULY 06, 2015 Jul 6th, 2015
Pacific NW Fertility first in the United States to offer innovative genetic testing prior to making embryos utilizing donor eggs. Diseases hidden in the combined DNA of sperm and eggs can be revealed before fertilization takes place in the IVF process.
NEW YORK & CAMBRIDGE, MA (BUSINESS WIRE) MARCH 19, 2015 Mar 19th, 2015
Lifeprint Group, the parent company for GenePeeks, Inc., a genetic information company focused on next-generation disease risk analysis, announced today that Mara Aspinall has joined the company’s board of Directors as Executive Chairman. Aspinall brings deep experience building and leading successful life science companies to support the company’s continued growth.
(BIO IT WORLD) MAY 22, 2014 May 22nd, 2014
GenePeeks has opened its in-silico nursery, formally lunching the Matchright screening service for families who are planning to use a sperm donor to conceive. GenePeeks was awarded patents in late January for algorithms that simulate potential offspring.
NEW YORK & CAMBRIDGE, MA (BUSINESS WIRE) JAN 27, 2014 Jan 27th, 2014
GenePeeks, Inc., a genetic technology company focused on pre-conception risk prediction, announced today it has been issued patent No. 8,620,594, titled “Method and System for Generating a Virtual Progeny Genome,” by the United States Patent and Trademark Office. The patent covers innovative algorithms that simulate the genetic interactions occurring naturally in human reproduction in order to create hypothetical “digital babies.”